Combiomed Research Group

07/10/2023

New doctor in the house!! 🎓
Parabéns Dr. Rubén Prieto, well done 👏✨

24/01/2022

We are very pleased to share a new article from the group in J.Med.Chem. 💊📄
This one focuses on an important series of adenosine A1 antagonists!
Congratulations to all the authors and partners!

Click on the link for more details of this work!

https://doi.org/10.1021/acs.jmedchem.1c01636

CiQUS-Centro de Investigación en Química Biolóxica e Materiais Moleculares Universidade de Santiago de Compostela
Uppsala University

We herein document a large collection of 108 2-amino-4,6-disubstituted-pyrimidine derivatives as potent, structurally simple, and highly selective A1AR ligands. The most attractive ligands were confirmed as antagonists of the canonical cyclic adenosine monophosphate pathway, and some pharmacokinetic...

27/08/2021

El investigador monfortino Rubén Prieto indaga sobre partes del organismo implicadas en el cáncer

16/07/2021

Today we are proud to announce that Ana Mallo Abreu, member of our research group, has been named Doctor with Sobresaliente "Cum laude" mention. Congratulations Ana!

02/06/2021

Celtarys Research, a start-up company from our research group (Universidade Santiago DE Compostela and CiQUS-Centro de Investigación en Química Biolóxica e Materiais Moleculares) has reached the final of the Emerging Technologies Competition organized by the Royal Society of Chemistry.

Celtarys Research SL will compete with other 5 projects in the health field on June 29 and 30 in a virtual final. Join the session: https://rsc.li/2SFl5Vv

Congratulations to all the team!👏

Each year we welcome applications from entrepreneurs who are developing technologies that have a strong chemistry component. View the 2021 winners and finalists here and find out about the live final.

13/04/2021

If you want to know more about Celtarys Research and fluorescent ligands see the recorded video of Maria Majellaro in the 4th ERNEST meeting!

Note that the programme uses Central European Time (CET). If you live outside this time zone, be aware of the time difference for live sessions.

11/03/2021

We are very happy to announce the creation of a new spin-off based on technologies developed in the ComBioMed Research Group.

Celtarys Research is a start-up company that develops and markets innovative chemical tools to disseminate the use of fluorescence-based methods in drug discovery.

Visit the webpage for more info: https://www.celtarys.com

Congratulations to everyone involved!

07/01/2021

Check our new Journal of Medicinal Chemistry publication! A library of 180 potent and selective A2B antagonists eliciting stereospecific binding modes and endowed with excellent antimetastatic effect.

https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01431

20/09/2020

The importance of concentration: The A2B receptor has the lowest affinity for adenosine of its entire family. This causes the receptor to be "asleep" under normal conditions, "waking up" when adenosine concentration is too high.

When does this happen? Adenosine is increased in situations of hypoxia, inflammation and cancer. The body interprets elevated adenosine as a signal of tissue damage.

What triggers? The body tries to stop the damage by inhibiting the immune system. This protects the tumor.

We are currently working on the development of molecules that selectively block adenosine receptors, specifically A2B, to avoid adenosine-mediated oncoprotection.

See more of our work at https://www.sotelolab.es and Twitter ().

Adenosine in immune cells by ComBiomed Research Group (Rubén Prieto) is licensed under CC BY-NC-ND 4.0.

08/08/2020

Adenosine and its relevance in cancer: the A2 receptor subset as a new immune checkpoint. Read more (): https://buff.ly/3fEalwk

03/08/2020

To be read (full text link): the next generation of cancer immunotherapy: small molecules

After decades of intense effort, therapeutics that leverage the immune system to fight cancer have now been conclusively demonstrated to be effective. Immunoncology has arrived and will play a key role in the treatment of cancer for the foreseeable future. ...